James T Palmer
Overview
Explore the profile of James T Palmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suchowerska A, Stokman G, Palmer J, Coghlan P, Pieterman E, Keijzer N, et al.
J Lipid Res
. 2022 Oct;
63(11):100293.
PMID: 36209894
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibits the clearance of low-density lipoprotein (LDL) cholesterol (LDL-C) from plasma by directly binding with the LDL receptor (LDLR) and sending the receptor...
2.
Evison B, Palmer J, Lambert G, Treutlein H, Zeng J, Nativel B, et al.
Bioorg Med Chem
. 2020 Feb;
28(6):115344.
PMID: 32051094
Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low density lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction...
3.
Palmer J, Axford L, Barker S, Bennett J, Blair M, Collins I, et al.
Bioorg Med Chem Lett
. 2014 Aug;
24(17):4215-22.
PMID: 25086682
A series of dual-targeting, alcohol-containing benzothiazoles has been identified with superior antibacterial activity and drug-like properties. Early lead benzothiazoles containing carboxylic acid moieties showed efficacy in a well-established in vivo...
4.
Axford L, Agarwal P, Anderson K, Andrau L, Atherall J, Barker S, et al.
Bioorg Med Chem Lett
. 2013 Nov;
23(24):6598-603.
PMID: 24239017
The discovery and optimisation of a new class of benzothiazole small molecules that inhibit bacterial DNA gyrase and topoisomerase IV are described. Antibacterial properties have been demonstrated by activity against...
5.
Burns C, Bourke D, Andrau L, Bu X, Charman S, Donohue A, et al.
Bioorg Med Chem Lett
. 2009 Sep;
19(20):5887-92.
PMID: 19762238
A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs). Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide). Details of synthesis and...
6.
Gauthier J, Chauret N, Cromlish W, Desmarais S, Duong L, Falgueyret J, et al.
Bioorg Med Chem Lett
. 2008 Jan;
18(3):923-8.
PMID: 18226527
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724. Substituting P1 and modifying the P2...
7.
Pan Z, Scheerens H, Li S, Schultz B, Sprengeler P, Burrill L, et al.
ChemMedChem
. 2006 Dec;
2(1):58-61.
PMID: 17154430
No abstract available.
8.
Setti E, Venkatraman S, Palmer J, Xie X, Cheung H, Yu W, et al.
Bioorg Med Chem Lett
. 2006 Jun;
16(16):4296-9.
PMID: 16750630
The synthesis and biological profile of a novel series of potent and selective inhibitors of cysteine protease cathepsin K (Cat K) are described. Pharmacokinetic evaluation of 12 indicated that some...
9.
Rydzewski R, Burrill L, Mendonca R, Palmer J, Rice M, Tahilramani R, et al.
J Med Chem
. 2006 May;
49(10):2953-68.
PMID: 16686537
Beginning with the peptide sequence Cbz-Ile-Glu(OtBu)-Ala-Leu found in PSI (3), a series of vinyl sulfones (VS) were synthesized for evaluation as inhibitors of the chymotrypsin-like activity of the 20S proteasome....
10.
Palmer J, Rydzewski R, Mendonca R, Sperandio D, Spencer J, Hirschbein B, et al.
Bioorg Med Chem Lett
. 2006 Apr;
16(13):3434-9.
PMID: 16644215
Using a scaleable, directed library approach based on orthogonally protected advanced intermediates, we have prepared a series of potent keto-1,2,4-oxadiazoles designed to explore the P(2) binding pocket of human mast...